Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Part of paid clinical trials in Fort Collins, Colorado.

Sponsor
Pfizer
Study ID
NCT06057402
Phase
PHASE4
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elranatamab — DRUG
    Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Study Details

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Key Dates

Start date
Oct 3, 2023
Status verified
Jun 2026
Primary completion
Feb 22, 2032
Completion
Feb 22, 2032

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Elranatamab
    Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Primary Outcome Measure

Incidence of nonserious adverse events (AEs) leading to permanent discontinuation [ Time Frame: A minimum of 90 days after the last dose of study drug ]

Central Contacts

Locations (14)

Find similar trials in Fort Collins, CO

By condition

Related Studies